Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 205

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society

Open access
Kanner, Andres M., Ashman, Eric, Gloss, David, Harden, Cynthia, Bourgeois, Blaise, Bautista, Jocelyn F., Abou-Khalil, Bassel, Burakgazi-Dalkilic, Evren, Llanas Park, Esmeralda, Stern, John, Hirtz, Deborah, Nespeca, Mark, Gidal, Barry, Faught, Edward, French, Jacqueline · 2018 · Neurology

Abstract

OBJECTIVE: To update the 2004 American Academy of Neurology guideline for managing treatment-resistant (TR) epilepsy with second- and third-generation antiepileptic drugs (AEDs). METHODS: 2004 criteria were used to systemically review literature (January 2003 to November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength. RESULTS: Forty-two articles were included. RECOMMENDATIONS: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment); rufinamide for Lennox-Gastaut syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency (Level B): lacosamide, eslicarbazepine, and extended-release topiramate for TRAFE (ezogabine production discontinued); immediate- and extended-release lamotrigine for generalized epilepsy with TR generalized tonic-clonic (GTC) seizures in adults; levetiracetam (add-on therapy) for TR childhood focal epilepsy (TRCFE) (1 month-16 years), TR GTC seizures, and TR juvenile myoclonic epilepsy; clobazam for LGS (add-on therapy); zonisamide for TRCFE (6-17 years); oxcarbazepine for TRCFE (1 month-4 years). The text presents Level C recommendations. AED selection depends on seizure/syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. This evidence-based assessment informs AED prescription guidelines for TR epilepsy and indicates seizure types and syndromes needing more evidence. A recent Food and Drug Administration (FDA) strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only for pediatric use) as add-on or monotherapy in persons ≥4 years of age and perampanel as monotherapy received FDA approval.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005755

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 22

  1. 10.1212/01.WNL.0000123693.82339.FC · DOI · Paper page
  2. 10.1212/01.WNL.0000123695.22623.32 · DOI · Paper page
  3. 10.1212/WNL.52.8.1540 · doi:10.1212/wnl.52.8.1540
  4. American Academy of Neurology. Clinical Practice Guidelines Process Manual, 2004 ed. St. Paul: The American Academy of Neurology; 2004. Available at: aan.com/Guidelines/Home/UnderDevelopment. Accessed January 30, 2010.
  5. 10.1212/01.WNL.0000167384.68207.3E · DOI · Paper page
  6. 10.1111/j.1528-1167.2007.01128.x · DOI · Paper page
  7. 10.1212/01.wnl.0000252941.50833.4a · DOI · Paper page
  8. 10.1016/S0140-6736(07)60460-7 · DOI · Paper page
  9. 10.1016/S0140-6736(98)10531-7 · DOI · Paper page
  10. 10.1001/archneur.1995.00540340081016 · DOI · Paper page
  11. 10.1016/S1474-4422(11)70154-5 · DOI
  12. 10.1111/j.1528-1167.2010.02670.x · DOI
  13. 10.1016/S0920-1211(99)00039-X · DOI · Paper page
  14. 10.1016/S0140-6736(95)90581-2 · DOI · Paper page
  15. 10.1111/j.1528-1157.1999.tb05562.x · DOI · Paper page
  16. 10.1177/0883073807303997 · DOI
  17. 10.1016/S0140-6736(07)60461-9 · DOI · Paper page
  18. 10.1056/NEJMoa0902014 · DOI · Paper page
  19. 10.1111/epi.12028 · DOI · Paper page
  20. 10.1212/01.WNL.0000048200.12663.BC · DOI
  21. 10.1034/j.1600-0404.2003.00093.x · DOI · Paper page
  22. 10.1016/S0920-1211(97)00025-9 · DOI · Paper page

Metadata

Authors
Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J.
Venue
Neurology
Published
2018-07-10
Volume
91
Issue
2
Pages
74-81
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2808405323
Cited by
205
References
2
FWCI
14.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. https://app.cochat.ai/papers/10.1212/wnl.0000000000005755
The paper
Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J. (2018). Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. https://doi.org/10.1212/wnl.0000000000005755

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.